GlassScriptPhysician profile
Lauren Ogden
NPI 1609909670
$2,511.06
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $376 · 2021: $775 · 2022: $426 · 2024: $18.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $18.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $18.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $465.78 | 2019-2022 | |
| Abbvie INC. | $309.88 | 2019-2022 | |
| Novo Nordisk INC | $292.21 | 2019-2022 | |
| Lilly USA, LLC | $189.56 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $165.25 | 2019-2021 | |
| Astellas Pharma US INC | $149.57 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $134.83 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $119.94 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $80.27 | 2019-2021 | |
| Glaxosmithkline, LLC. | $52.95 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $48.65 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $47.47 | 2020-2021 | |
| Duchesnay USA Incorporated | $44.87 | 2019 | |
| Merck Sharp & Dohme LLC | $44.66 | 2019-2022 | |
| Pfizer INC. | $41.02 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $37.66 | 2021-2022 | |
| Therapeuticsmd, INC. | $33.71 | 2019-2021 | |
| Shire North American Group INC | $30.20 | 2019 | |
| Amneal Pharmaceuticals LLC | $24.43 | 2021-2022 | |
| Lundbeck LLC | $21.33 | 2022 | |
| Bausch Health US, LLC | $19.83 | 2019 | |
| Allergan, INC. | $19.22 | 2020 | |
| Sumitomo Pharma America, INC. | $18.58 | 2024 | Gemtesa |
| Collegium Pharmaceutical, INC. | $16.98 | 2022 | |
| Arbor Pharmaceuticals, INC. | $16.41 | 2021 | |
| Sanofi Pasteur INC. | $15.07 | 2019 | |
| Millicent US INC | $14.85 | 2019 | |
| Amarin Pharma, INC. | $14.42 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.40 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.87 | 2022 | |
| Lupin INC. | $13.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Ogden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.